[go: up one dir, main page]

WO2020172592A1 - Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes - Google Patents

Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes Download PDF

Info

Publication number
WO2020172592A1
WO2020172592A1 PCT/US2020/019314 US2020019314W WO2020172592A1 WO 2020172592 A1 WO2020172592 A1 WO 2020172592A1 US 2020019314 W US2020019314 W US 2020019314W WO 2020172592 A1 WO2020172592 A1 WO 2020172592A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
genes
tissue
biological sample
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/019314
Other languages
English (en)
Inventor
Pradip K. Majumder
Biswanath MAJUMDER
Aaron Goldman
Padhma D. Radhakrishnan
Saravanan Thiyagarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitra Rxdx Inc
Original Assignee
Mitra Rxdx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Rxdx Inc filed Critical Mitra Rxdx Inc
Publication of WO2020172592A1 publication Critical patent/WO2020172592A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • This application pertains to prognostic and therapeutic methods involving predicting the response of a cancer patient to an anti-cancer drug based on a modulation of gene expression.
  • Cancer is a highly heterogenous disease with significant inter-patient as well as intra-patient variability. Given the toxicity profiles and high treatment cost of anti-cancer therapeutics, it is of utmost importance to identify subpopulation of patients who are most likely to respond to a given dmg. Precision medicine has made significant headway in using biomarker guided strategies to match patients to drags. However, the number of patients who harbor an actionable genetic mutation is low, and the fraction of patients actually benefitting from a therapy targeting such mutation is still lower (J Clin. Oncol. 2015 Sep 1;33(25):2753- 62).
  • Cancer immunotherapy has made significant progress in recent years, however as with many other blockbuster anti-cancer therapies (such as Avastin), clinical success is very unpredictable, largely owing to the lack of biomarkers that will .predict personalized response.
  • an anti-PD-1 drag Nivolumab
  • Nivolumab has shown 20-30% response rates in patients with any degree of PD-L1 expression, but durable response has also been observed in patients with low or no detectable PD-L1 expression ( Future Oncol. 2018; 14: 2415).
  • biomarker panel based on a ratio of expression levels of two sets of genes. These genes are modulated differentially in individual patients in response to an anti-cancer drag (such as an immune checkpoint inhibitor). Based on the modulation of expression of the genes under drag pressure in a patient, the patient’s response or the durability of response to the anti-drag can be predicted.
  • anti-cancer drag such as an immune checkpoint inhibitor
  • the present invention relates to a method to predict a patient s response to an anti-cancer drug, the method comprising determining a ratio of an expression level of a first set of genes to an expression level of a second set of genes in a drug treated biological sample to obtain a post-treatment gene ratio.
  • the method further comprises comparing the post-treatment gene ratio with a reference value, wherein if the post-treatment gene ratio is greater than the reference value, the anti-cancer drug is predicted to show response in the patient and if the post-treatment gene ratio is less than the reference value, the anti -cancer drug is predi cted to show no response in the patient.
  • the fi rst set of genes is at least 5 genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and the second set of genes is at least 5 genes selected from a second gene panel consisting of ARG1,
  • IDOl IDOl
  • IL 10 IDOl
  • NOS2A NOS2A
  • STAT3 STAT3
  • TGFB1 TGFB1.
  • the present invention relates to a method to predict a patient’s response to an anti-cancer drug, the method comprising determining a ratio of an expression level of a first set of genes to an expression level of a second set of genes in a control biological sample to obtain a pre-treatment gene ratio and determining a ratio of an expression level of the first set of genes to an expression level of the second set of genes in a drug treated biological sample to obtain a post-treatment gene ratio, wherein the anti-cancer drug is an immune checkpoint inhibitor.
  • the method further comprises comparing the posttreatment gene ratio with a pre-treatment gene ratio, wherein if the post-treatment gene ratio is greater than the pre-treatment gene ratio, the immune checkpoint inhibitor is predicted to show response in the patient and if the post-treatment gene ratio is less than the pre-treatment gene ratio, the immune checkpoint inhibitor is predicted to show no response in the patient.
  • the first set of genes is CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and INF
  • the second set of genes is ARG1, IDOL IL10, NOS2A, STAT3, and TGFBl .
  • the invention relates to a kit comprising a first set of probes for detecting expression of each gene in the first set of genes and a second set of probes for detecting expression of each gene in the second set of genes, wherein first set of genes is at least 5 genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, 1L12RB2, LTA, NFKBIA, PRFl, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and the second set of genes is at least 5 genes selected from the second gene panel consisting of ARG1, IDOl, IL10, NOS2A, STAT3, and TGFBl.
  • FIG. 1 Schematic of an embodiment for prediction of response using in-vivo drug treated biological sample and control biological sample.
  • FIG. 2 Schematic of an embodiment for prediction of response with in-vitro drug treated biological sample and control biological sample.
  • FIG. 3 Determination of differential gene ratio and prediction of response for each patient treated with PD-1 inhibitor using in-vivo drug treated biological sample and control biological sample.
  • FIG. 4A Predicted response and clinical response for each patient treated with PD-1 inhibitor using in-vitro drug treated biological sample and control biological sample. Black bars indicate actual clinical response and grey bars indicate actual clinical nonresponse.
  • FIG. 4B Confusion matrix for positive and negative predictive values.
  • FIG. 5 Determination of differential gene ratio and prediction of response for each patient using in-vitro drug treated biological sample (tissue-sections cultured in presence of PD-1 inhibitor, Nivolumab) and control biological sample.
  • the cancer refers to a cancer patient.
  • the cancer can be a solid cancer or a hematological cancer.
  • the cancer is a cancer of head and neck.
  • the cancer of head and neck is head and neck squamous cell carcinoma (HNSCC).
  • the patient is a head and neck cancer patient.
  • HNSCC head and neck squamous cell carcinoma
  • a drug is an anti-cancer drug.
  • An anti-cancer drug can be a single anti-cancer drug or a combination of anti-cancer drugs.
  • Non-limiting examples of an anti-cancer drug includes a chemotherapeutic agent such as a cytostatic or a cytotoxic agent, a targeted anti-cancer agent (such as an antibody or small molecule drug targeting a signal transduction pathway in cancer), an immunotherapeutic agent, and the like.
  • the anti-cancer drug is an immunotherapeutic agent.
  • an immunotherapeutic agent includes but is not limited to an immune check point inhibitor (such as molecules directed to PD-1, PD-L1, or CTLA-4 etc.), an immune-stimulating agent (such as an agonistic antibody against OX-40), an adoptive cell therapy (such as CAR-T cell, Tumor Infiltrating Lymphocyte etc.), a cancer vaccine, a cytokine (such as Interleukin-2, Interferon-a etc.), and the like.
  • the anti-cancer drug is an immune checkpoint inhibitor.
  • Non-li miting examples of immune checkpoint inhibitor include PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor and the like.
  • the immune checkpoint inhibitor is a PD-1 inhibitor, such as a small molecule or an antibody.
  • the small molecule or the antibody binds to PD-1, thereby preventing the interaction of PD-1 with its ligand, PD-L1.
  • the PD-1 inhibitor is an antibody directed to PD-1, such as nivolumab or pembrolizumab.
  • an anti-cancer drug is a single anti-cancer drug such as an immune check point inhibitor.
  • the immune check point inhibitor is nivolumab or pembrolizumab.
  • an anti-cancer drug is a combination of two or more immune checkpoint inhibitors (for example, nivolumab and an antibody directed to CTLA-4, such as
  • ipilimumab a combination of an immune checkpoint inhibitor (as example, nivolumab) with another class of anti-cancer drug (for example, cisplatin).
  • an immune checkpoint inhibitor as example, nivolumab
  • another class of anti-cancer drug for example, cisplatin
  • biological sample refers to any tissue or biological material obtained from a patient.
  • tissue includes tumor tissue, skin tissue, hair follicles, bone marrow, blood etc.
  • a biological material is a non-tissue, mostly acellular biological sample.
  • Non-limiting examples of biological material includes saliva, sputum, pleural effusion, urine, sweat, serum, plasma, nail clippings and the like.
  • a biological sample without limitation, is any substance obtained from a patient in which a biomarker, such as the expression level of a gene, can be determined.
  • the biological sample is a tumor tissue obtained from a patient.
  • the biological sample is a blood sample obtained from a patient.
  • a drug treated biological sample is a tissue or a biological material that has been treated with an anti-cancer drug either in-vivo or in-vitro.
  • a biological sample that has been treated with an anti-cancer drug in-vivo is also referred to as an in-vivo drug treated biological sample.
  • a biological sample that has been treated with an anti-cancer drug in-vitro is also referred to as an in-vitro drug treated biological sample.
  • a control biological sample is a tissue or a biological material that has not been treated with the anti-cancer drug either in- vivo or in-vitro.
  • the anti-cancer drug is an immune checkpoint inhibitor.
  • the immime checkpoint inhibitor is a PD-1 inhibitor.
  • the PD-1 inhibitor is nivolumab or pembrolizumab.
  • a drug treated biological sample is a tissue or a biological material that has been treated with an anti-cancer drug in-vivo, that is an in-vivo drug treated biological sample.
  • the biological sample is obtained from a patient after the patient is treated with an anti-cancer drug.
  • the biological sample is obtained from the patient after the patient is treated with at least one dose of the anti-cancer drug.
  • the biological sample is obtained from the patient after the patient is treated with multiple doses of the anti-cancer drug.
  • the biological sample is obtained from the patient after the patient has completed a treatment cycle with the anti-cancer drug.
  • a control biological sample is a tissue or a biological material that has not been treated with the anticancer drug in-vivo.
  • the biological sample is obtained from the patient before the patient is treated with the anti-cancer drug.
  • the biological sample is a tumor tissue or blood.
  • a control biological sample is a tumor tissue obtained from a patient before the patient is treated with an anti-cancer drug and a drug treated biological sample is a tumor tissue obtained from the patient after the patient is treated with the anti-cancer drug.
  • a control biological sample is a blood sample obtained from a patient before the patient is treated with an anti -cancer drug and a drug treated biological sample is a blood sample obtained from the patient after the patient is treated with the anti-cancer drug.
  • a drug treated biological sample is a tissue or a biological material that has been treated with an anti-cancer drug in-vitro, that is an in-vitro drug treated biological sample.
  • a drug treated biological sample is a tissue-section which is cultured in presence of the anti-cancer drug, wherein the tissue-section is a section of a tumor tissue obtained from a patient.
  • a control biological sample is a tissue-section which is not treated with an anti-cancer drug in- vitro.
  • a control biological sample is a tissue-section which is not cultured in presence of the anti -cancer drug, wherein the tissue-section is a section of the tumor tissue obtained from the patient.
  • a tissue-section which is not cultured in presence of an anti-cancer drug refers to a tissue-section which is not cultured in-vitro or a tissue-section which is cultured in-vitro, but in absence of the anti-cancer drug.
  • a control biological sample is a tissue-section which is cultured in absence of the anti-cancer drug.
  • a control biological sample is a tissue-section which is not cultured in-vitro.
  • the tissue-section may be processed for biomarker analysis, such as determination of the expression level of a gene, without the tissue-section being cultured prior to such analysis.
  • the patient is not treated with the same anti-cancer drug before the tumor tissue is obtained.
  • Treating a patient with an anti-cancer drug refers to administering into the patient an anti-cancer drug.
  • An anti-cancer drug can be administered by any means known to a person skilled in the art. Non-limiting examples of means of administering an anti-cancer drug includes intravenous administration, intramuscular administration, intrathecal administration, oral administration, and the like.
  • a biological sample can be obtained by any method known in the art, including but not limited to surgery, biopsy, aspiration, phlebotomy, thoracentesis, swab collection and the like.
  • a reference value can be a pre-determined cut-off score or can be determined from an expression level of a set of genes in a control biological sample.
  • the reference value can be detemiined from an expression level of a first set of genes and an expression level of a second set of genes, in a control biological sample.
  • a reference value is a pre-treatment gene ratio, wherein the pre-treatment gene ratio is a ratio of an expression level of a first set of genes to an expression level of a second set of genes determined in the control biological sample.
  • a response can be determined by any means and/or criteria known to a person of ordinary skill in the art, such as but not limited to the RECIST or the WHO criteria.
  • a response can be any one of tumor response (such as detennined from a change in tumor size), overall survival (OS), progression-free survival (PFS), time to progression (TTP), recurrence, and the like.
  • a patient who is predicted to respond to an anti-cancer drug is predicted to achieve a complete response, a partial response, or have increased OS, PFS, or TTP, if treated with the anti-cancer drug.
  • a patient who is predicted to respond to an anti-cancer drug is predicted to have a complete or partial regression in tumor size, if treated with the anti-cancer drug.
  • a patient who is predicted not to respond to an anti-cancer drug is predicted to have a progressive disease or have decreased OS, PFS, or TTP, if treated with the anti-cancer drug.
  • a patient who is predicted not to respond to an anti-cancer drug is predicted to have a progression in tumor size, if treated with the anticancer drug.
  • An increased or decreased OS, PFS, and/or TTP can be predicted with respect to a median OS, a median PFS, and/or a median TTP for a particular anti-cancer drug.
  • a patient who is predicted to respond to an anti-cancer drug is predicted to have an OS or PFS which is longer than the median OS or PFS respectively for that anti-cancer drug and a patient who is predicted not to respond to an anti-cancer drug, is predicted to have an OS or PFS which is shorter than the median OS or PFS respectively for that anti-cancer drug.
  • Probe as used herein means an oligonucleotide that is capable of specifically hybridizing under hybridization conditions to a transcript expressed by a gene in a set of genes (such as a first set of genes or a second set of genes).
  • the term“transcript” includes RNA transcribed from the gene, and/or specific spliced variants thereof and/or fragments of such RNA and spliced variants.
  • the method of the disclosure relates to determining an expression level of a first set of genes, wherein the first set of genes is at least 5 genes (such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 genes) selected from a first gene panel consisting of CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRFl, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1.
  • the method of the disclosure relates to determining an expression level of a first set of genes, wherein the first set of genes is at least
  • the first set of genes is CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, INF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1.
  • the first set of genes is CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and INF.
  • the method relates to determining an expression level of a second set of genes, wherein the second set of genes is at least 5 genes (such as 5 or 6 genes) selected from a second gene panel consisting of ARG1, IDOl, IL10, NOS2A, STAT3 and TGFB1.
  • Non-limiting examples of second set of genes include ARG1, IDOl, IL10, NOS2A and STAT3, or IDOl, IL10, NOS2A, STAT3 and TGFB1, or ARGl, 1L10, NOS2A, STAT3 and TGFB1, or ARGl, IDOl, IL10, STAT3 and TGFB1, or ARGl, IDOl, IL10, NOS2A and TGFB1, and the like.
  • the second set of genes is ARGl, IDOl, IL10, NOS2A, STAT3, and TGFB1.
  • An expression level of a gene may be an absolute expression level of the gene or a normalized expression level of the gene.
  • An expression level of a gene can be normalized by any method known in the art to obtain a normalized expression level.
  • the expression level is normalized by correcting the absolute expression level of a gene by comparing its expression to the expression of a control gene such as a housekeeping gene that is constitutively expressed.
  • Non-limiting examples of genes for normalization include housekeeping genes such as the Actin gene ACTB, Lactate dehydrogenase A (LDHA), Ribosomal 18S gene, Phosphoglycerate kinase 1 (PGK1), Ubiquitin C (UBC), Transferrin receptor (TFRC) and b-Glucuronidase (GUSB).
  • normalization method further comprises Removal of Un wanted Vari ation (RUV) method to correct the unwanted technical effects introduced in the dataset.
  • Positive and negative controls ERCC spike-in controls
  • a normalization of gene expression is done using housekeeping genes, followed by removal of unwanted variation.
  • Removal of unwanted variation can be done by any known method, for example by using any commercial or open source packages such as RUVSeq (Bioconductor) (Risso D, et al. (2014)“Normalization of RNA-seq data using factor analysis of control genes or samples.” Nature Biotechnology, 32(9), 896-902).
  • an expression level of a set of genes refers to a single expression level, such as a mean expression level or a median expression level, determined from individual expression levels of each gene in the set of genes.
  • an expression level of a first set of genes CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and TNF refers to a mean expression level or a median expression level detennined from individual expression levels of CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRFl, STAT1 and TNF genes.
  • an expression level of a second set of genes ARG1, IDOl, IL10, NOS2A, STAT3 and TGFB1 refers to a mean expression level or a median expression level determined from the individual expression levels of ARG1, IDO1 , IL10, NOS2A, STAT3 and TGFB1 genes.
  • the individual expression levels are normalized to obtain normalized expression levels of each gene in the set of genes.
  • a mean expression level or a median expression level is determined from the normalized expression levels.
  • the normalized expression levels can be transformed in any convenient way before determination of the mean expression level or the median expression level.
  • the individual expression levels are normalized, and log transformed prior to determination of the mean expression level or the median expression level.
  • individual expression levels of each gene in the first set of genes are determined.
  • the expression level of each gene is normalized, and log transformed to obtain a normalized and log transformed expression level.
  • a median expression level is determined from the normalized and log transformed expression levels of all genes in the first set of genes to obtain an expression level of the first set of genes.
  • individual expression levels of each gene in the second set of genes are determined.
  • the expression level of each gene is normalized, and log transformed to obtain a normalized and log transformed expression level.
  • a median expression level is determined from the normalized and log transformed expression levels of all genes in the second set of genes to obtain an expression level of the second set of genes.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes is determined in a drug treated biological sample to obtain a post-treatment gene ratio.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes is determined in a control biological sample to obtain a pre-treatment gene ratio.
  • an expression level of a gene is determined using any method known to a person skilled in the art.
  • an expression level of a gene is determined by quantifying the level of a gene expression product such as a protein or an RNA.
  • the gene expression product can be quantified in a biological sample, a secretion of the biological sample, or in a supernatant of a culture medium used for culturing the biological sample.
  • the expression level of a gene is determined by quantifying the RNA level.
  • a person skilled in the art will appreciate that a number of methods can be used to isolate RNA from a biological sample (such as a drug treated biological sample or a control biological sample). RNA can be extracted from fresh, frozen or fixed biological sample.
  • RNA can be extracted using any commercially available RNA extraction kits.
  • RNA is extracted from a tissue, such as a tumor tissue.
  • RNA is extracted from blood.
  • the expression level of a gene is determined by quantifying the protein level.
  • methods for quantifying protein level includes western blot or enzyme-linked immunosorbent assay (ELISA).
  • Non-limiting examples of methods to determine an expression level of a gene include, quantitative reverse transcription-PCR (RT-qPCR), various quantitative isothermal amplification methods (for example nucleic acid sequence-based amplification (NASBA), reverse transcription loop-mediated isothennal amplification (RT-LAMP) and others), norther blot, microarray, RNA sequencing, or any other method for quantifying an expression level of a gene.
  • RT-qPCR quantitative reverse transcription-PCR
  • various quantitative isothermal amplification methods for example nucleic acid sequence-based amplification (NASBA), reverse transcription loop-mediated isothennal amplification (RT-LAMP) and others
  • norther blot for example nucleic acid sequence-based amplification (NASBA), reverse transcription loop-mediated isothennal amplification (RT-LAMP) and others
  • norther blot for example nucleic acid sequence-based amplification (NASBA), reverse transcription loop-mediated isothennal amplification (RT-LAMP
  • a method to determine an expression level of a gene includes using the n Counter® Analysis System marketed by NanoString® Technologies (Seattle, Washington USA). This system, which is described by Geiss et al., Nature Biotechnol. 2(3):317-325 (2008), utilizes a pair of nucleotide probe, namely, a capture probe and a reporter probe, each comprising a 35- to 50-base sequence complementary to the transcript to be detected.
  • the capture probe additionally includes a short common sequence coupled to an immobilization tag, e.g. an affinity tag that allows the complex to be immobilized for data collection.
  • the reporter probe additionally includes a detectable signal or label, e.g.
  • the color-coded tag on each transcript is counted and tabulated for each target transcript to yield the expression level of each transcript in the sample.
  • the method relates to determining an expression level of a first set of genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and determining an expression level of a second set of genes selected from a second gene panel consisting of ARG1, IDOl , 1L10, NOS2A, STAT3, and TGFBl.
  • Some embodiments relate to methods of determining a ratio of an expression level of a first set of genes to an expression level of a second set of genes, in a drug treated biological sample to obtain a posttreatment gene ratio, wherein the first set of genes is at least 5 genes selected from the first gene panel CASP1, CCL3, CCL4, CCL5, CCRl, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and the second set of genes is at least 5 genes selected from the second gene panel ARGl, IDOl, IL10, NOS2A, STAT3, and TGFBl.
  • the first set of genes is CASP1, CCL3, CCL4, CCL5, CCRl, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and TNF and the second set of genes is ARGl, IDOl, IL10, NOS2A, STAT3, and TGFBl.
  • the post-treatment gene ratio is compared to a reference value.
  • the reference value is a predetermined cut-off score.
  • the predetermined cut-off score is determined from the expression level of each gene in a set of genes, in a control pool of patients.
  • the predetermined cut-off score can be a mean, a median, or a percentile determined from the expression levels of the genes in a set of genes in the control pool of patients.
  • the reference value is a pre-treatment gene ratio, wherein the pre-treatment gene ratio is a ratio of an expression level of the first set of genes to an expression level of the second set of genes in a control biological sample.
  • a control biological sample (such as a blood sample or a tumor tissue) is obtained from a patient before the patient is treated with an anti-cancer drug.
  • a ratio of an expression level of a first set of genes to an expression level of a second set of genes is determined in the control biological sample to obtain a pre-treatment gene ratio.
  • the patient is then treated with the anti-cancer drug.
  • treating the patient with the anti-cancer drug refers to administering into the patient at least one dose of the anti-cancer drug.
  • a drug treated biological sample is obtained from the patient after the patient is treated with the anti-cancer drug.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes is detennined in the drug treated biological sample to obtain a post-treatment gene ratio. If the post-treatment gene ratio is greater than the pre-treatment gene ratio, the patient is predicted to respond to the anti-cancer drug and if the post-treatment gene ratio is less than the pre-treatment gene ratio, the patient is predicted not to respond to the anti-cancer drug.
  • the method of the invention further comprises administering into the patient the anti-cancer drug if the posttreatment gene ratio is greater than the pre-treatment gene ratio.
  • the method of the invention further comprises stopping the administration of the anti-cancer drug into the patient if the post-treatment gene ratio is less than the pre-treatment gene ratio.
  • the anti-cancer drug is an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor is a PD-1 inhibitor.
  • the PD-1 inhibitor is nivolumab or pembrolizumab.
  • the drug treated biological sample is a tissue-section which is cultured in presence of an anti-cancer drug, wherein the tissue-section is a section of a tumor tissue obtained from a patient.
  • a tissue-section which is cultured in presence of an anti-cancer drug is also referred to as a drug treated tissue-section.
  • the control biological sample is a tissue-section which is not cultured in presence of the anti-cancer drug, wherein the tissue-section is anotiier section of the tumor tissue obtained from the patient.
  • a tissue- section which is not cultured in presence of the anti-cancer drug is a tissue-section which is not cultured in-vitro or a tissue-section which is cultured in-vitro, but in absence of the anti- cancer drug.
  • the control biological sample is a tissue-section which is not cultured in-vitro.
  • the control biological sample is a tissue-section which is cultured in-vitro, but in absence of the anti-cancer drug.
  • the control biological sample is a tissue-section which is cultured in-vitro in absence of the anticancer drug and in presence of a vehicle control.
  • a vehicle control can comprise an isotype control.
  • a tissue-section which is not cultured in presence of an anti-cancer drug is also referred to as a control tissue-section.
  • a ratio of an expression level of a first set of genes to an expression level of a second set of genes is determined in the control biological sample to obtain a .pre-treatment gene ratio.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes is determined in the drug treated biological sample to obtain a post-treatment gene ratio.
  • the method of the invention further comprises administering into the patient the anti-cancer drug if the post-treatment gene ratio is greater than the pre-treatment gene ratio.
  • the anti-cancer drug is an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor is a PD-1 inhibitor.
  • the PD-1 inhibitor is nivolumab or pembrolizumab.
  • a tumor tissue can be obtained from a patient by any means known to an ordinary skilled person. Examples of such means include surgery or biopsy.
  • a tissue -section having a thickness of about 100 pm to about 3000 pm is used for culturing in-vitro.
  • the tissue-section having a volume of about 0.2 cm 3 to about 0.5 cm 3 is used for culturing in-vitro.
  • the tissue-sections are non-homogenized sections, that is the tissue-sections are not dissociated mechanically, chemically or enzymatically into single cell suspension prior to culture in-vitro.
  • tissue- sections retain the intratumoral heterogeneity, signaling pathways, immune contexture, and the stromal compartment of the native tumor tissue.
  • the tissue- sections are dissociated mechanically, chemically or enzymatically into single cell suspension prior to culture in-vitro.
  • a tissue-section is cultured in-vitro using any in-vitro culture technique known to a person skilled in the art.
  • An extracellular matrix (ECM) composition is coated on a platform to obtain an ECM composition-coated platform.
  • ECM composition-coated platform In some embodiments, the tissue- sections are cultured on the ECM composition-coated platform.
  • An ECM composition can be any ECM composition used in the culture of tumor tissue.
  • the ECM composition can be any off-the-shelf ECM composition, such as Matrigel TM (Coming Inc., USA) or a customized ECM composition.
  • the components of the ECM composition are specific for the cancer type and grade of the tumor tissue.
  • the components of the ECM composition are selected by subjecting a sample of a tumor tissue to one or more assays to identify components of the ECM present in the tumor tissue (example of assays include mass spectrometry, such as liquid chromatography-mass spectrometry (LCMS)).
  • assays include mass spectrometry, such as liquid chromatography-mass spectrometry (LCMS)).
  • the ECM composition comprises ECM components identified from a sample of bone marrow.
  • the ECM composition comprises ECM components identified from a sample of blood plasma.
  • the ECM composition comprises ECM components identified from an autologous sample (e.g., the tumor tissue is derived from the same individual as the sample from which the ECM components are identified).
  • the ECM composition comprises ECM components identified from a heterologous sample (e.g., the tumor tissue is derived from a different individual than the sample from which the ECM components are identified).
  • the ECM composition is a customized and defined composition comprising one or more of collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Osteopontin, Laminin, Decorin, and Tenascin C.
  • the ECM composition comprises at least three components selected from a group consisting of collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Osteopontin, Laminin, Decorin, and Tenascin C.
  • collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Osteopontin, Laminin, Decorin, and Tenascin C We have previously established and optimized an ECM composition for culturing tumor tissue-sections that mimics the native human tumor environment (see US Patent No. 2014/0228246, incorporated herein in its entirety).
  • the platform can be any platform used in cell culture, including but not limited to, a plate, base, flask, dish, petri-plate and petri-dish.
  • the platform can be made of any material suitable for being coated with the ECM composition.
  • the platform is coated with the ECM composition by depositing a liquid mixture comprising the ECM composition on the platform and allowing the liquid mixture to dry.
  • the liquid mixture is an aqueous mixture hi some embodiments, the liquid mixture is allowed to dry at a temperature at least about 25 °C.
  • the platform is washed with an appropriate solution (for example a buffer, such as PBS) following coating with the ECM composition.
  • the substrate has been stored at a temperature no greater than about 4 °C prior to combination a culture medium.
  • Tissue-sections can be cultured in any culture medium known to a person skilled in the art.
  • culture medium include without limitation, DMEM (Dulbecco's Modified Eagle Medium) or RPMI 1640 (Roswell Park Memorial Institute Medium).
  • one or more of serum, plasma and peripheral blood nuclear cells are added to the ECM composition-coated platfonn to obtain a tumor microenvironment platform.
  • the tissue-sections are cultured in-vitro on the tumor microenvironment platform. Culturing a tissue-section on a tumor
  • microenvironment platfomi refers to culturing the tissue-section on an ECM composition- coated platform in the presence of one or more of serum, plasma and PBNC.
  • serum, plasma and PBNC There is no limitation on the order of addition of the tissue-section, or one or more of serum, plasma and PBNC.
  • one or more of serum, plasma and PBNC is obtained from the patient, that is one or more of serum, plasma and PBNC is autologous to the patient.
  • one or more of serum, plasma and PBNC is not obtained from the patient, that is one of one or more of serum, plasma and PBNC is heterologous to the patient.
  • a tumor microenvironment platform for culturing tumor tissue- sections that mimics the native human tumor environment (see US Patent No. 2014/0228246, incorporated herein in its entirety).
  • a tumor microenvironment platform comprises an ECM composition-coated platform and at least one of serum, plasma and PBNC.
  • the ECM composition comprises at least three components selected from a group consisting of collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Osteopontin, Laminin, Decorin, and Tenascin C.
  • a tissue-section can be cultured for any period of time, such as for 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, or 240 hours.
  • culturing of the tissue-sections is carried out at a temperature ranging from about 30° C to about 40° C, such as at about 37° C.
  • culturing of the tumor tissue is carried out at about 5% CO2.
  • the expression level of a gene can be determined at the end of the culture period or at any predetermined timepoint during the culture period.
  • the expression level of a gene can be determined by quantifying a gene expression product on the tissue-sections or in a supernatant of the culture medium used for culturing the tissue-sections.
  • the method further comprises performing one or more in-vitro assays on the control tissue-section and the drug treated tissue-section.
  • the one or more in-vitro assays are selected from a group consisting of a cell viability' assay, a cell death assay, a cell proliferation assay, a tumor morphology assay, a tumor stroma content assay, a cell metabolism assay, a senescence assay, a cytokine profile assay, an enzyme activity assay, a tumor and stromal cell expression assay, and any combination thereof.
  • the assay for cell viability include MTT assay, WST assay, ATP uptake assay and glucose uptake assay.
  • the assay for cell proliferation and metabolism include, Ki-67 assay, PCNA (proliferating nuclear cell antigen) assay, ATP/ADP ratio assay, and glucose uptake assay.
  • the assay for cell death include, for example, lactose dehydrogenase (LDH) assay, activated Caspase-3 assay, activated Caspase 8 assay, Nitric Oxide Synthase assay, and TUNEL assay.
  • the assay for senescence include, for example, senescence-associated beta-galactosidase staining.
  • the assay for tumor morphology and tumor stroma include, for example, hematoxylin & eosin staining (H&E) for tumor cell content, size of the tumor cells, ratio of viable cells/dead cells, ratio of tumor cells/normal cells, tumor/macrophage ratio, nuclear size, density, and integrity, apoptotic bodies, and mitotic figures.
  • the in-vitro assay is an immunohistochemical assay, including multiplexed immunohistochemical assays, such as for evaluating simultaneous activity/infiltration of immune cells and/or signaling/activity components.
  • the in-vitro assay is a quantitative or qualitative assay including, for example, ELISA, blotting (e.g., Western, Norther, or Southern blot), LC/MS, bead based assay, immune-depletion assay, and chromatographic assay.
  • an in-vitro assay readout is obtained from each of the one or more in-vitro assays.
  • an in-vitro assay readout is an input in a predictive model. A prediction of response or non-response is generated by the predictive model.
  • an in-vitro assay readout is obtained from each of the one or more in-vitro assays performed on a control tissue-section and an in-vitro assay readout is obtained from each of the one or more in-vitro assays performed on a drug treated tissue- section.
  • an in-vitro assay readout is a numeric value.
  • an assessment score is determined for each of the one or more in-vitro assays, wherein an assessment score is a ratio of an in-vitro assay readout obtained from an in-vitro assay performed on a drug treated tissue-section to an in-vitro assay readout obtained from the in-vitro assay performed on a control tissue-section.
  • the method further comprises multiplying each assessment score with a corresponding weightage coefficient to obtain a weighted assessment score.
  • the weighted assessment scores from one or more in-vitro assays are combined to obtain a sensitivity index.
  • the sensitivity index provides a prediction of response or non-response.
  • the sensitivity index is generated by the predictive model on inputting the in-vitro assay readouts into the predictive model. In some embodiments, all the steps are performed as a computer-implemented method. In some embodiments, the sensitivity index is generated such that a sensitivity index value above a threshold value predicts response (such as a complete response or a partial response) and a sensitivity index value below the threshold value predicts no response (such as a progressive disease) in the patient.
  • the sensitivity index is generated such that a sensitivity index value above an upper threshold value predicts complete response, a sensitivity index value betw een the upper threshold value and a lower threshol d value predicts partial response, and a sensitivity index value below the lower threshold value predicts non response in the patient.
  • the method further comprises generating a prediction of response or non-response from the predictive model using the in- vitro assay readouts as inputs.
  • the method of the invention further comprises administering into the patient the anti-cancer drug.
  • the post-treatment gene ratio is less than the pre-treatment gene ratio, and the predictive model generates a prediction of non-response, the patient is predicted not to respond to the anti-cancer drug. In such embodiments, the anti-cancer drug is not administered into the patient.
  • the method of the invention relates to a method of treatment of a cancer patient. In some embodiments, the method comprises obtaining from the patient a tumor tissue.
  • the method further comprises determining in a control tissue- section, a ratio of an expression level of a first set of genes to an expression level of a second set of genes to obtain a pre-treatment gene ratio, wherein the control tissue-section is a section of the tumor tissue which is not cultured in presence of an anti-cancer drug and determining in a drug treated tissue-section, a ratio of an expression level of the first set of genes to an expression level of the second set of genes to obtain a post-treatment gene ratio, wherein the drug treated tissue-section is a section of the tumor tissue which is cultured in presence of the anti-cancer drug.
  • the control tissue-section and the drug treated tissue-section are cultured on a tumor microenvironment platfonn.
  • the tumor microenvironment platform comprises an ECM composition-coated platform and at least one of serum, plasma and PBNC.
  • at least one of serum, plasma and PBNC is autologous to said patient hi some embodiments, the ECM composition comprises at least three components selected from a group consisting of collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Osteopontin, Laminin, Decorin, and Tenascin C.
  • the method of the invention comprises administering into the patient the anti-cancer drug if the post-treatment gene ratio is greater than the pre-treatment gene ratio.
  • the anti -cancer drug is an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor is a PD-1 inhibitor.
  • the PD-1 inhibitor is nivolumab or pembrolizmnab.
  • the invention provides a method of treatment of a cancer patient.
  • a method of treatment includes determining whether or not to continue treatment with an anti-cancer drug or determining whetiier or not to change the dose or schedule of an anti-cancer drug.
  • a control biological sample (such as a blood sample or a tumor tissue) is obtained from a patient before the patient is treated with an anti-cancer drug.
  • a ratio of an expression level of a first set of genes to an expression level of a second set of genes is determined in the control biological sample to obtain a .pre-treatment gene ratio. The patient is then treated with the anti -cancer drug.
  • treating the patient with the anti-cancer drug comprises administering into the patient at least one dose of the anti-cancer drug. In some embodiments, treating the patient with the anti-cancer drug comprises administering into the patient multiple doses of the anti-cancer drug. In some embodiments, treating the patient with the anti-cancer drug comprises administering into the patient multiple doses of the anti-cancer drug to complete at least one treatment cycle.
  • a drug treated biological sample (such as a blood sample or a tumor tissue) is obtained from the patient after the patient is treated with the anti-cancer drug.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes is determined in the drug treated biological sample to obtain a post-treatment gene ratio.
  • the patient is predicted to respond to the anti-cancer drug and if the post-treatment gene ratio is less than the pre-treatment gene ratio, the patient is predicted not to respond to the anti -cancer drug.
  • the me thod of the invention further comprises administering into the patient the anti-cancer drug if the post-treatment gene ratio is greater than the pre-treatment gene ratio.
  • the method of the invention further comprises stopping the administrati on of the anti-cancer drug into the patient if the post-treatment gene ratio is less than the pre-treatment gene ratio.
  • the method comprises changing the dose of the anti-cancer drug if the post-treatment gene ratio is less than the pre-treatment gene ratio.
  • the anti-cancer drug is an immune checkpoint inhibitor.
  • the immune checkpoint inhibitor is a PD-1 inhibitor.
  • the PD-1 inhibitor is nivolumab or pembrolizumab.
  • the invention provides a kit for assaying a biological sample to determine an expression level of a first set of genes and an expression level of a second set of genes.
  • the kit comprises a first set of probes for detecting expression of each gene in the first set of genes and a second set of probes for detecting expression of each gene in the second set of genes.
  • the kit comprises, for each target transcript in the set of genes, at least one probe for the target transcript.
  • the first set of genes is at least 5 genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and the second set of genes is at least 5 genes selected from the second gene panel consisting of ARG1, IDOl, IL10, NOS2A, STAT3, and TGFB1.
  • the first set of genes is CASP1, CCL3, CCL4, CCL5, CCRl , CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1,
  • the kit may also comprise a second set of probes for detecting expression of a set of normalization genes.
  • the normalization gene set consists of 10 to 1000 genes, e.g., this gene set may consist of at least any of 25, 50, 75, 100, 150, 200, 300, 400, 500, 600, 700, 800 or 900 genes.
  • Embodiment 1 A method to predict a patient’s response to an anti-cancer drug, the method comprising, determining in a drug treated biological sample, a ratio of an expression level of a first set of genes to an expression level of a second set of genes to obtain a post-treatment gene ratio, wherein the first set of genes is at least 5 genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCR1 , CCR2, CCR5, CTLA4, IFNv, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, wherein the second set of genes is at least 5 genes selected from a second gene panel consisting of ARG1, IDOl, 1L10, NOS2A, STAT3, and TGFB1; and comparing the post-treatment gene ratio with a reference value, wherein if the post-treatment gene ratio is greater than
  • Embodiment 2 The method of embodiment 1, wherein the reference value is a pretreatment gene ratio, wherein the pre-treatment gene ratio is a ratio of an expression level of the first set of genes to an expression level of the second set of genes in a control biological sample.
  • Embodiment 3 The method of embodiment 2, wherein the control biological sample is a tissue, or a biological material obtained from the patient, wherein the tissue or the biological material is obtained from the patient before the patient is treated with the anti-cancer drug.
  • Embodiment 4 The method as in any one of embodiments 1-3, wherein the drug treated biological sample is a tissue or a biological material obtained from the patient, wherein the tissue or the biological material is obtained from the patient after the patient is treated with the anti-cancer drug.
  • Embodiment 5 The method of embodiment 2, wherein the control biological sample is a tissue-section which is not cultured in presence of the anti-cancer drug, wherein the tissue- section is a section of a tumor tissue obtained from the patient.
  • Embodiment 6 The method as in any one of embodiments 2 and 5, wherein the control biological sample is a tissue-section which is cultured in absence of the anti-cancer drug, wherein the tissue-section is a section of a tumor tissue obtained from the patient.
  • Embodiment 7 The method as in any one of embodiments 1 , 5, and 6, wherein the drug treated biological sample is a tissue-section which is cultured in presence of the anti-cancer drug, wherein the tissue-section is a section of the tumor tissue obtained from the patient.
  • Embodiment 8 The method as in any one of embodiments 1, 5, 6, and 7, wherein the drug treated biological sample, the control biological sample, or both the drug treated biological sample and the control biological sample are cultured on a tumor microenvironment platform, wherein the control biological sample is a tissue-section which is cultured in absence of the anti-cancer drug, wherein the tissue-section is a section of a tumor tissue obtained from the patient and wherein the drug treated biological sample is a tissue-section which is cultured in presence of the anti-cancer drug, wherein the tissue-section is another section of the tumor tissue obtained from the patient.
  • the control biological sample is a tissue-section which is cultured in absence of the anti-cancer drug
  • the tissue-section is a section of a tumor tissue obtained from the patient
  • the drug treated biological sample is a tissue-section which is cultured in presence of the anti-cancer drug, wherein the tissue-section is another section of the tumor tissue obtained from the patient.
  • Embodiment 9 The method as in any one of embodiments 5-8, further comprising performing one or more in-vitro assays on the drug treated biological sample and the control biological sample, wherein the one or more in-vitro assays are selected from a group consisting of a cell viability assay, a cell death assay, a cell proliferation assay, a tumor moiphology assay, a tumor stroma content assay, a cell metabolism assay, a senescence assay, a cytokine profile assay, an enzyme activity assay, a tumor and stromal cell expression assays, and any combination thereof.
  • the one or more in-vitro assays are selected from a group consisting of a cell viability assay, a cell death assay, a cell proliferation assay, a tumor moiphology assay, a tumor stroma content assay, a cell metabolism assay, a senescence assay, a cytokine profile assay, an enzyme activity assay,
  • Embodiment 10 The method as in any one of embodim ents 8 and 9, wherein the tumor microenvironment platform comprises an ECM composition-coated platform and at least one of serum, plasma and peripheral blood nuclear cells, wherein at least one of serum, plasma and peripheral blood nuclear cells is autologous to said patient.
  • Embodiment 11 The method as in any one of embodiments 1-10, wherein the first set of genes is CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and INF.
  • the first set of genes is CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and INF.
  • Embodiment 12 The method as in any one of embodiments 1-11, wherein the second set of genes is ARG1, IDOl, IL10, NOS2A, STATS, and TGFB1.
  • Embodiment 13 The method as in any one of embodiments 1-12, wherein the anti-cancer drug is an immune checkpoint inhibitor.
  • Embodiment 14 Tlie method as in any one of embodiments 1-12, wherein the anti -cancer drug is a PD-1 inhibitor.
  • Embodiment 15 The method as in any one of embodiments 1-12, wherein the anti-cancer drug is nivolumab or pembrolizumab.
  • Embodiment 16 The method as in any one of embodiments 1-15, wherein the patient is a head and neck cancer patient.
  • Embodiment 17 The method as in any one of embodiments 1-16, further comprising administering into the patient the anti-cancer drug, if the post-treatment gene ratio is greater than the reference value.
  • Embodiment 18 A method to predict a patient’s response to an anti-cancer drug, the method comprising, determining in a control biological sample, a ratio of an expression level of a first set of genes to an expression level of a second set of genes to obtain a pre-treatment gene ratio, determining in a drug treated biological sample, a ratio of an expression level of the first set of genes to an expression level of the second set of genes to obtain a post-treatment gene ratio, wherein the anti -cancer drug is an immune checkpoint inhibitor, wherein the first set of genes is CASP1, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, 1L12RB2, LTA, NFKBIA, PRF1, STAT1 and TNF, and wherein the second set of genes is ARG1, 1D01, 1L10, NOS2A, STAT3, and TGFB1; and comparing the post-treatment gene ratio with the pre-treatment gene ratio, wherein if the post-treatment gene ratio is greater
  • Embodiment 19 The method of embodiment 18, wherein the control biological sample is a tissue, or a biological material obtained from the patient, wherein the tissue or the biological material is obtained from the patient before the patient is treated with the immune checkpoint inhibitor.
  • Embodiment 20 The method as in any one of embodiments 18 and 19, wherein the drug treated biological sample is a tissue or a biological material obtained from the patient, wherein the tissue or the biological material is obtained from the patient after the patient is treated with the immune checkpoint inhibitor.
  • Embodiment 21 The method of embodiment 18, wherein the control biological sample is a tissue-section which is cultured in absence of the immune checkpoint inhibitor, wherein the tissue-section is a section of a tumor tissue obtained from the patient.
  • Embodiment 22 Tlie method as in any one of embodiments 18 and 21 , wherein the drug treated biological sample is a tissue-section which is cultured in presence of the immune checkpoint inhibitor, wherein the tissue-section is a section of the tumor tissue obtained from the patient.
  • Embodiment 23 The method as in any one of embodiments 18, 21, and 22, wherein the drug treated biological sample and the control biological sample are cultured on a tumor microenvironment platform, wherein the control biological sample is a tissue-section which is cultured in absence of the immune checkpoint inhibitor, wherein the tissue-section is a section of a tumor tissue obtained from the patient, and wherein the drug treated biological sample is a tissue-section which is cultured in presence of the immune checkpoint inhibitor, wherein the tissue-section is another section of the tumor tissue obtained from the patient.
  • Embodiment 24 The method as in any one of embodiments 18, 21, 22, and 23, further comprising performing one or more in-vitro assays on the drug treated biological sample and the control biological sample, wherein the one or more in-vitro assays are selected from a group consisting of a cell viability assay, a cell death assay, a cell proliferation assay, a tumor morphology assay, a tumor stroma content assay, a cell metabolism assay, a senescence assay, a cytokine profile assay, an enzyme activity assay, a tumor and stromal cell expression assays, and any combination thereof.
  • the one or more in-vitro assays are selected from a group consisting of a cell viability assay, a cell death assay, a cell proliferation assay, a tumor morphology assay, a tumor stroma content assay, a cell metabolism assay, a senescence assay, a cytokine profile assay, an enzyme activity as
  • Embodiment 25 The me thod as in any one of embodiments 23 and 24, wherein the tumor microenvironment platform comprises an ECM composition-coated platform and at least one of serum, plasma and peripheral blood nuclear cells, wherein at least one of serum, plasma and peripheral blood nuclear cells is autologous to said patient.
  • the tumor microenvironment platform comprises an ECM composition-coated platform and at least one of serum, plasma and peripheral blood nuclear cells, wherein at least one of serum, plasma and peripheral blood nuclear cells is autologous to said patient.
  • Embodiment 26 The method as in any one of embodiments 18-25, wherein the immune checkpoint inhibitor is a PD-1 inhibitor.
  • Embodiment 27 The method as in any one of embodiments 18-26, wherein the immune checkpoint inhibitor is nivolumab or pembrolizumab.
  • Embodiment 28 The method as in any one of embodiments 18-27, further comprising administering into the patient the immune checkpoint inhibitor, if the post-treatment gene ratio is greater than the pre-treatment gene ratio.
  • Embodiment 29 The methods as in any one of embodiments 18-28, wherein the patient is a head and neck cancer patient.
  • Embodiment 30 A kit comprising a first set of probes for detecting expression of each gene in the first set of genes and a second set of probes for detecting expression of each gene in the second set of genes, wherein first set of genes is at least 5 genes selected from a first gene panel consisting of CASP1, CCL3, CCL4, CCL5, CCRl , CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1, STAT4, TNF, CD38, TBX21, CLU, CD55, CSF2, CXCR3, GATA3 and SPP1, and the second set of genes is at least 5 genes selected from the second gene panel consisting of ARGl , IDOl, ILIO, NOS2A, STAT3, and TGFB1.
  • HNSCC patients were recruited from multiple hospitals with ethics committee approval. Patient-consented tumor biopsies or surgical tissues, in addition to blood specimens ( ⁇ 10 ml) were also obtained.
  • the anti-PD-1 antibodies (or PD-1 inhibitors), Nivolumab (Opdivo, Bristol Myers Squibb) and Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp), were stored in aliquots at -80 °C for one-time use.
  • Nivolumab, Pembrolizumab and Isotype control (Ultra- LEAFTM Purified Human IgG4 Isotype Control, Biolegend) were used at the concentration of 132 mg/ml, 65.7 mg/ml and 132 mg/ml, respectively.
  • Tumor tissues were dissected into tissue-sections approximately 2-4 mm 3 thickness using MaCwin tissue chopper. Tissue-sections were randomized to preserve the heterogeneity in culture. Tissue-sections were maintained in customized ECM composition- coated platforms.
  • Peripheral blood nucleated cells PBNCs
  • the PBNCs were co-cultured with tissue-sections. Autologous plasma was added to the culture at the concentration of 2%. All experiments were performed either in triplicates or quadruplicates contingent on the sample size received.
  • the PanCancer Immune Panel was used to profile 770 genes.
  • NanoString probe hybridization was performed at either NanoString headquarters (Seattle, WA) or at Mitra Biotech (Woburn, MA). RNA hybridized with probes were run either on the SPRINT or MAX machines. Raw counts obtained for each sample were calibrated and normalized using nSolver software version 4.0 (NanoString Technologies). Positive control normalization using six positive control probes was performed on NanoString CodeSet.
  • Housekeeping mean normalization was performed using two housekeeping genes included in the CodeSet.
  • the nonnalized expression levels were determined for each of the following first set of genes CASPl, CCL3, CCL4, CCL5, CCR1, CCR2, CCR5, CTLA4, IFNg, IL12RB2, LTA, NFKBIA, PRF1, STAT1 and TNF and each of the following second set of genes ARG1, IDOL IL10, NOS2A, STAT3, and TGFB1.
  • the normalized expression levels were log transformed for each gene in the first set of genes and for each gene in the second set of genes.
  • a median expression level was determined from the normalized and log transformed expression levels of all genes in the first set of genes to obtain an expression level of the first set of genes.
  • a median expression level was determined from the normalized and log transformed expression levels of all genes in the second set of genes to obtain an expression level of the second set of genes.
  • a ratio of an expression level of the first set of genes to an expression level of a second set of genes was determined in the control biological sample to obtain a .pre-treatment gene ratio.
  • a ratio of an expression level of the first set of genes to an expression level of the second set of genes was determined in the dmg treated biological sample to obtain a post-treatment gene ratio.
  • control such as control tissue-section
  • treatment groups such as drug treated tissue-section
  • Expression counts from nSolver were adjusted for library size using the R package DESeq2 (vl.20.0) Prefiltering of low-count genes was performed to keep the genes with minimum of 5 counts in at least two samples. The resulting genes were then used to determine differentially expressed genes between groups. Unless otherwise noted, genes with a log2 fold change above 1 and padj ⁇ 0.05 were classified as upregulated and genes with a log2 fold change below 1 and padj ⁇ 0.05 were classified as downregulated. Genes found differentially expressed in DESeq2 analysis were used to perform PCA using ClustVis (https://biit.cs.ut.ee/cliistvis/) and FactoMineR version 1.41.
  • IP A Ingenuity Pathway Analysis (IP A, version 2.3) (QIAGEN Inc.,
  • Cell Counting Kit-8 (CCK-8, Dojindo Inc), a colorimetric assay, was used to measure cell viability . Briefly, one tenth volume of CCK-8 solution (20 mL) was added to 200 mL of superatant of culture media and incubated at 37 °C for 3 to 4 h in a humidified incubator (5%, C02). The resulting incubation media was collected and absorbance was measured at 450 nm using a microplate reader (Bio-Rad).
  • Tissue-section was gently lysed and subjected for the extraction. 12.5m1 of tissue lysates were mixed with 12.5mI of Lu-Lu mixer (DCS Bioluminescence Kit, #TCA- LITE) and luminescence reading was taken immediately. The data are normalized with total protein concentration (DC protein assay reagent, BioRad).
  • tissue culture supernatants 25 ml were processed to measure the secreted profile of cytokine analytes and incubated with 25 ml of beads for 1 hr and 25 ml biotinylated detection antibody for 30 min.
  • the complex was spiked with 25 ml of Streptavidin-PE and analyzed for cytokine profiling using Luminex200 (Luminex, USA) platform.
  • Luminex200 Luminex, USA
  • the cell-free superatant 25 ml was run on one or multiple Millipore Milliplex plates, customized for the analytes selected. For each plate, a set of standard curves was run to ensure accurate evaluation of the concentration of each analyte and the integrity of the assay. Each plate was read on the Luminex 200.
  • Concentrations of each analyte was interpolated from their respective standard curve using the Milliplex Analyst software (Millipore, USA). Data from multiple plates were compiled and analyte fold changes, relative to vehicle controls, was calculated using an appropriate graphing and statistical software.
  • Tissue-sections were deparaffmized followed by rehydration and soaked in Antigen Unmasking Solution (Vector Labs) for 10 minutes followed by retrieval. Following protein blocking, FFPE tissue sections were incubated with appropriate primary antibodies (anti-Ki-67, Dako, envision kit, 1:400, and anti-caspase 3c (rabbit) from CST, 1:600 dilution). Validated positive and negative controls were included for every IHC assay. Each 1HC result was evaluated by two independent experts and any differences in observation both experts came to a consensus as described previously. Changes in the frequency of proliferating or dividing population of tumor cells in the explant slices were evaluated using Ki-67 or caspase 3c scoring (i.e.
  • Ki-67 or caspase3c positive cells per section were incubated for an optimized time period in humidified condition (Signal stain(R) Boost IHC detection reagent F1RP Rabbit,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des kits pour prédire la réponse d'un patient à un médicament anticancéreux. Le procédé consiste à déterminer, dans un échantillon biologique traité par médicament, un rapport d'un niveau d'expression d'un premier ensemble de gènes à un niveau d'expression d'un second ensemble de gènes pour obtenir un rapport de gène post-traitement et à comparer le rapport de gène post-traitement à une valeur de référence. Si le rapport génique post-traitement est supérieur à la valeur de référence, il est prévu que le patient réponde au médicament anticancéreux et si le rapport génique post-traitement est inférieur à la valeur de référence, il est prévu que le patient ne réponde pas au médicament anticancéreux.
PCT/US2020/019314 2019-02-22 2020-02-21 Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes Ceased WO2020172592A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962809468P 2019-02-22 2019-02-22
US201962809463P 2019-02-22 2019-02-22
US62/809,463 2019-02-22
US62/809,468 2019-02-22

Publications (1)

Publication Number Publication Date
WO2020172592A1 true WO2020172592A1 (fr) 2020-08-27

Family

ID=72144413

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2020/019314 Ceased WO2020172592A1 (fr) 2019-02-22 2020-02-21 Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes
PCT/US2020/019313 Ceased WO2020172591A1 (fr) 2019-02-22 2020-02-21 Procédé pour prédire la réponse d'un patient à un médicament anticancéreux à partir d'un niveau d'expression d'un ensemble de gènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2020/019313 Ceased WO2020172591A1 (fr) 2019-02-22 2020-02-21 Procédé pour prédire la réponse d'un patient à un médicament anticancéreux à partir d'un niveau d'expression d'un ensemble de gènes

Country Status (1)

Country Link
WO (2) WO2020172592A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4112746A1 (fr) * 2021-07-02 2023-01-04 STRATIFYER Molecular Pathology GmbH Procédé pour prédire la réponse clinique face à un inhibiteur de point de contrôle immunitaire basé sur un prétraitement avec celui-ci
GB202305410D0 (en) * 2023-04-13 2023-05-31 Rosser Julie Analysis of treatment efficacy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140228246A1 (en) * 2011-10-04 2014-08-14 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
US20160222118A1 (en) * 2013-03-15 2016-08-04 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US20170306416A1 (en) * 2014-10-08 2017-10-26 Felipe Bedoya Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180051347A1 (en) * 2016-07-12 2018-02-22 The Regents Of The University Of California Methods for immunotherapy-based treatment and assessment of cancer
US20180357361A1 (en) * 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094992A1 (fr) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Biomarqueurs de signature du gène ifn-gamma de la réponse tumorale à des antagonistes de pd-1
US11078278B2 (en) * 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US20190361006A1 (en) * 2017-02-08 2019-11-28 Mitra Rxdx, Inc. Method of predicting clinical outcome of anticancer agents
US11913075B2 (en) * 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140228246A1 (en) * 2011-10-04 2014-08-14 Mitra Biotech Private Limited Ecm composition, tumor microenvironment platform and methods thereof
US20160222118A1 (en) * 2013-03-15 2016-08-04 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US20170306416A1 (en) * 2014-10-08 2017-10-26 Felipe Bedoya Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180051347A1 (en) * 2016-07-12 2018-02-22 The Regents Of The University Of California Methods for immunotherapy-based treatment and assessment of cancer
US20180357361A1 (en) * 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAO ET AL.: "Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma", CANCER SCIENCE, vol. 102, no. 8, 9 June 2011 (2011-06-09), pages 1522 - 1531, XP055733532 *

Also Published As

Publication number Publication date
WO2020172591A1 (fr) 2020-08-27

Similar Documents

Publication Publication Date Title
Dangaj et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors
AU2020200114B2 (en) Methods and assays relating to circulating tumor cells
CN109777872B (zh) 肺癌中的t细胞亚群及其特征基因
Kanwar et al. Identification of genomic signatures in circulating tumor cells from breast cancer
Evans et al. Gene and protein expression signature of endometrial glandular and stromal compartments during the window of implantation
Bonaccorsi-Riani et al. Molecular characterization of acute cellular rejection occurring during intentional immunosuppression withdrawal in liver transplantation
US20210277480A1 (en) Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
Yang et al. Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer
He et al. HOXA5 is amplified in glioblastoma stem cells and promotes tumor progression by transcriptionally activating PTPRZ1
WO2020172592A1 (fr) Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes
EP2418288B1 (fr) Procédé pour le diagnostic et le pronostic de la tolérance dans la greffe de foie au moyen de tissus hépatiques
de la Iglesia-San Sebastián et al. Digital PCR improves sensitivity and quantification in monitoring CAR-T cells in B cell lymphoma patients
Li et al. Exploring GZMK as a prognostic marker and predictor of immunotherapy response in breast cancer: unveiling novel insights into treatment outcomes
Tang et al. Ionizing radiation induces epithelial–mesenchymal transition in human bronchial epithelial cells
Kaira et al. Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence
Lv et al. Functional assessment of four novel immune-related biomarkers in the pathogenesis of clear cell renal cell carcinoma
Shen et al. β-catenin/TCF4-induced SCUBE3 upregulation promotes ovarian cancer development via HIF-1 signaling pathway
CA3152279A1 (fr) Procedes pour determiner la reactivite a une therapie anti-facteur de necrose tumorale dans le traitement du psoriasis
Li et al. IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer
CN113862269B (zh) tsRNA分子及其用途
CN113652487B (zh) 人C11orf86 mRNA在评估肺腺癌患者预后中的应用及检测试剂盒
Zhang et al. G6PD drives glioma invasion by regulating SQSTM1 protein stability
He et al. BANF1 is a novel prognostic biomarker linked to immune infiltration in head and neck squamous cell carcinoma
Ranti HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer
KR102431271B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20759590

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20759590

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05/04/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20759590

Country of ref document: EP

Kind code of ref document: A1